Osteoarthritis
IDEA reports positive phase III results for targeted analgesic IDEA-033
Published in Drug Week, September 8th, 2006
The company simultaneously announced that it has gained exclusive control over the global rights to IDEA-033, after reacquiring for consideration the Northern American license from its previous partner in the territory.
IDEA-033 was outlicensed in February 2003 to McNeil Consumer & Specialty Pharmaceuticals for the U.S. and Canada. The recent shift in the partner's focus to pediatric products provided IDEA with an opportunity to reacquire these IDEA-033 rights. IDEA now...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-08)
More Articles from Drug Week
- Drug Delivery
Low temperature sensitive liposome-doxorubicin may improve drug delivery to solid tumors - Drug Development
Human primary renal cells used as model for toxicity assessment of chemotherapeutic drugs - Pharmacokinetics
Interactions between simvastatin and omega-3-acid ethyl esters were examined - Systemic Lupus Erythematosus
Human Genome Sciences launches phase III clinical development program for LymphoStat-B - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - Addiction Medicine
GABA-mimetic drugs differently affect cocaine-evoked hyperlocomotion and sensitization - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
